Do We Need Aging Clocks—or Better Answers to Specific Health Questions?
Aging clocks can be useful research instruments without being universal clinical scores. Their value depends on the question, comparator, validation and decision.
- Published
- Last updated
- Last reviewed
Useful existing argument retained; observational prediction and model criticism are not clinical recommendations.
The question is not whether aging clocks are inherently useful or useless. It is whether a particular model adds information for a defined task. A tool built to predict chronological age, a tool that estimates disease risk and a tool intended to monitor an intervention should not be judged by the same criterion. Sources: Biomarkers of aging for the identification and evaluation of longevity interventions.; Do we actually need aging clocks?.
So the answer to the headline question is not a clean yes or no. We probably do need aging clocks — but not in the way many people currently talk about them. What the field needs most is not one universal “true age” machine. It needs validated, context-specific measures that are useful for particular jobs: enriching clinical trials, monitoring response, stratifying risk, and connecting molecular changes to clinically meaningful outcomes. The real argument, then, is less about whether clocks should exist than about what kind of clocks are worth building and what evidence they should have to earn their place. Sources: Biomarkers of aging for the identification and evaluation of longevity interventions.; Validation of biomarkers of aging..
An attractive number is not the same as a useful decision
This is not a trivial objection. If a model can predict heart failure, disability, dementia risk, or mortality better than a biological-age summary number can, then the summary number may be more elegant than necessary. A neat clock can compress information for non-specialists, but that does not automatically make it the best scientific or clinical tool. The same npj Aging paper argues that one should ask whether striving for a better biological-age estimate, rather than improving direct health-outcome prediction, is truly worthwhile. Sources: Do we actually need aging clocks?.
That critique lands hardest on clocks presented as universal truth machines. A clock that says you are “57 biologically” may be psychologically compelling, but if it cannot clearly outperform existing risk models or help guide an actual decision, it risks becoming more narrative device than medical instrument. That is why context of use is more informative than a claim of abstract superiority. Sources: Do we actually need aging clocks?; Validation of biomarkers of aging..
The perspective “Do we actually need aging clocks?” argues for judging clocks against the practical tasks they are meant to solve. It is a methodological argument, not a trial demonstrating superiority of a particular alternative. A direct risk model may be the relevant comparator when the intended question is disease risk. Sources: Do we actually need aging clocks?.
Prediction, response and surrogacy are different achievements
This is where many public discussions run ahead of the evidence. Observational association is not the same thing as intervention sensitivity, and cross-sectional performance is not the same thing as longitudinal usefulness. The validation review explicitly notes that cross-sectional studies cannot establish within-individual sensitivity to change — a key requirement if clocks are going to be used in clinical trials. That matters because a clock that predicts age or mortality in a cohort is not automatically a good readout of whether a drug, diet, or exercise program truly changed the biology of aging in one person. Sources: Validation of biomarkers of aging..
A 2023 Cell framework organizes aging biomarkers by intended use, while the 2024 validation review emphasizes analytical and clinical validation. These are research frameworks. FDA’s surrogate-endpoint explanation adds the regulatory distinction: evidence that an intervention changes a marker is not automatically evidence that the change predicts a specific clinical benefit. Sources: Biomarkers of aging for the identification and evaluation of longevity interventions.; Validation of biomarkers of aging.; FDA facts: biomarkers and surrogate endpoints.
That is not a side note. It cuts to the heart of a lot of rejuvenation and consumer testing rhetoric. If a clock has not been shown to work robustly in the exact setting where it is being used, the number it returns may be less a measurement than a projection. Sources: Validation of biomarkers of aging..
Organ-specific information does not automatically become actionability
Oh and colleagues used plasma proteomics to estimate aging-related signatures across 11 organs in five cohorts. The associations with outcomes support further risk-model investigation. They do not establish that testing organ age and acting on it improves outcomes, or that an organ-specific score is always preferable to an existing clinical measure. Sources: Organ aging signatures in the plasma proteome track health and disease..
Information can be lost when heterogeneous processes are compressed into one score. But more dimensions do not guarantee better decisions either. The question is whether the additional information changes a validated decision, not whether the dashboard looks more biologically detailed. Sources: Organ aging signatures in the plasma proteome track health and disease.; Do we actually need aging clocks?.
Wearable models extend the measurement question
PpgAge illustrates how a physiological signal can support large-scale age modeling. Its observational findings do not establish that lowering a wearable-derived age score improves health. The dedicated wearable article examines this distinction; it is not evidence that every signal responding to behavior measures aging rate. Sources: A wearable-based aging clock associates with disease and behavior..
Taken together, these studies suggest that the future of clocks may be less about one number that rules them all and more about a family of biologically and clinically grounded estimators. Sources: Biomarkers of aging for the identification and evaluation of longevity interventions.; Validation of biomarkers of aging..
| Intended task | Useful comparison | Unresolved if omitted |
|---|---|---|
| Understand biology | Reproducible associations and mechanistic experiments | Whether the model learned a causal process. |
| Predict an outcome | Direct outcome models and conventional predictors | Incremental value and calibration. |
| Monitor intervention response | Repeatability, controls and clinical outcomes | Meaning of a within-person shift. |
| Communicate a result | Uncertainty and a clearly bounded interpretation | Whether simplicity implies false certainty. |
Sources: Do we actually need aging clocks?; Validation of biomarkers of aging..
A more useful conclusion than “best biological-age test”
So do we actually need aging clocks? Yes — but only if we stop asking them to be more universal than the biology allows. The field does not need endless new clocks that merely predict chronological age with cosmetic sophistication. It needs validated tools that are explicit about what they measure, what populations they work in, how uncertain their predictions are, and what decisions they are meant to inform. Sources: Do we actually need aging clocks?; Biomarkers of aging for the identification and evaluation of longevity interventions..
For professional assessment, ask for the intended use, training target, validation population, uncertainty and decision consequence before interpreting the age number. This is not a consumer ranking or a guide to personal test results. The measurement-comparison article provides the platform-level overview; this record asks whether the age-model framing itself earns its place. Sources: Validation of biomarkers of aging.; Do we actually need aging clocks?.
Update triggers
Reassess when external validation shows meaningful incremental benefit, a controlled intervention connects marker change with clinical outcomes, or a regulator qualifies a measure for a defined use. Another accurate chronological-age prediction alone would not settle the clinical question. Sources: Validation of biomarkers of aging.; FDA: About biomarkers and qualification.
Related intelligence
Aging Biomarkers Compared: What Each Measure Captures—and What It Cannot Prove; Wearables as Aging Biomarkers: Prediction, Daily Variation and Clinical Use.